Recent News

• 12.12.2025 - Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
• 12.12.2025 - Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
• 11.26.2025 - Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
• 11.25.2025 - Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
• 11.19.2025 - Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
• 11.18.2025 - Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
• 11.14.2025 - Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
• 10.29.2025 - Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
• 10.29.2025 - Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
• 10.10.2025 - Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

Recent Filings

• 11.25.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 11.25.2025 - EX-99.1 EX-99.1
• 11.25.2025 - 8-K Current report
• 11.14.2025 - 8-K Current report
• 11.14.2025 - EX-99.1 EX-99.1
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities